Stock Analiz

Exicure, Inc. XCUR

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$1.08Market cap $7M
Open the interactive analysis →

Exicure, Inc. (XCUR) is a healthcare company listed in the US with a market value of about $7M.

Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is financial health (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -114%.

About Exicure

Exicure is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $1M in 2016 to $500000 in 2024, a decline of about 8.7% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 582% over three years (dilution for shareholders).

Score: 0.2 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B7.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-99.3%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-100.0%
Revenue growth (5 yrs, per year)-100.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)3774.2%
ROIC (5-yr avg.)-113.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$0$500000$0$29M-$483000$17M$1M$118000$10M$1M
Net income-$5M-$10M-$17M-$3M-$64M-$25M-$26M-$22M-$11M-$17M
Free cash flow-$9M-$3M-$10M-$36M-$36M-$42M$235000-$20M-$21M-$5M
EPS (diluted)$-0.79$-4.75$-10.55$-2.80$-108.50$-42.00$-69.00$-81.00$-163.50$-22405.27
Net margin—-1940.2%—-9.0%13271.6%-148.5%-2029.5%-18994.1%-113.3%-1635.2%
ROIC-91.5%-76.0%-154.7%-6.5%-240.9%-29.5%-30.9%-66.6%-41.9%-199.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Exicure pay a dividend?

Not currently.

Is Exicure a good stock to buy?

We do not give buy or sell advice. Exicure scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.